Blog

Saul Priceman: Phase 1 trial with PSCA-CAR T cell therapy in patients with mCRPC

Photo of Saul Priceman from Caryn Lerman/LinkedIn

Jun 15, 2024, 07:37

Saul Priceman: Phase 1 trial with PSCA-CAR T cell therapy in patients with mCRPC

Saul Priceman, Associate Professor at City of Hope, made the following post on X:

“Proud of our work published today in Nature Medicine, sharing results from our phase 1 trial with PSCA-CAR T cell therapy in patients with mCRPC. Big collaborations work Tanya Dorff, Stephen Forman, Peter Kuhn, Lior Pachter! Thank you Prostate Cancer Foundation for your support!”

Read further.
Source: Saul Priceman/X

cancer City of Hope clinical trial results Lior Pachter mCRPC Nature Medicine OncoDaily Oncology Peter Kuhn Prostate Cancer Foundation prostate cancer research PSCA-CAR T cell therapy Saul Priceman Stephen Forman Tanya Dorff

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Agenus and Tanner Pharma Partner to Expand Global Access to BOT/BAL

Bispecific Antibody M701 Offers a Novel Treatment Option for Malignant Ascites

Special Coverage